Bosutinib Reduces the Efficacy of Dasatinib in Triple-negative Breast Cancer Cell Lines
- Tarpley, Mike
- Abdissa, Temesgen
- Johnson, Gary L.
- Scott, John E.
DOIAbstract
Background—Triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Dasatinib and bosutinib are FDA-approved Src/Abl kinase inhibitor drugs. Dasatinib potently inhibits the proliferation of many TNBC cell lines. Material and Methods—The cell viability/proliferation for a panel of 4 TNBC cell lines was measured by detection of cellular ATP levels and cell numbers directly determined by automated cell counting. Results—Bosutinib (≤1 μM) had little to no inhibitory activity on cell viability/proliferation, while dasatinib-alone generated potent IC50 values of <100 nM. Combination treatment of cells with both dasatinib and bosutinib resulted in reduced efficacy of dasatinib in all four cell lines, with two of them displa...
Add to ORKG